Purespring Therapeutics
PrivateLast Round
Series B
Oct 9, 2024
Est. Valuation
$176.4M
Total Funding Raised
$227.18M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Purespring Therapeutics is a biotechnology company that develops AAV gene therapies to treat kidney diseases by targeting the podocyte.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Purespring Therapeutics Comparables
Compare Purespring Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Walden Biosciences | 77% | |
| Torque Bio, Inc. | 76% | |
| Borealis Biosciences | 72% | |
Purespring Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 9, 2024 | ||||
| Series A | Jul 30, 2021 | ||||
| Series A | Nov 19, 2020 |
Key People
Founding team and executive leadership
Purespring Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B |
| Syncona | Series B, Series A |
| British Patient Capital | Series B |
| Gilde Healthcare | Series B |
| Sofinnova Partners | Series B |
| Syncona Limited | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 151% MoM, reaching 2.7K.
- Nov 25, 2025
Team to present at Piper Sandler's 37th Annual Healthcare Conference in December.
Purespring Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Purespring Therapeutics's valuation, stock price, and market status.